SARS-CoV-2 infection-related deregulation of blood lipids in a patient with -/-LDLR familial homozygous hypercholesterolemia: A case report

[1]  Beata Franczyk,et al.  The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management , 2022, Biomedicines.

[2]  Chengyu Liu,et al.  Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19 , 2022, Frontiers in Nutrition.

[3]  M. Radzina,et al.  Intriguing findings of liver fibrosis following COVID-19 , 2021, BMC Gastroenterology.

[4]  H. Bian,et al.  Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management , 2021, Lipids in Health and Disease.

[5]  M. Larsen,et al.  HDL proteome remodeling associates with COVID-19 severity , 2021, Journal of Clinical Lipidology.

[6]  Deepak L. Bhatt,et al.  Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 , 2021, Journal of the American College of Cardiology.

[7]  G. FitzGerald,et al.  The roles of lipids in SARS-CoV-2 viral replication and the host immune response , 2021, Journal of Lipid Research.

[8]  A. Mangoni,et al.  Cholesterol and Triglyceride Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression , 2021, Frontiers in Public Health.

[9]  H. Pichler,et al.  SARS-CoV-2 spike protein removes lipids from model membranes and interferes with the capacity of high density lipoprotein to exchange lipids , 2021, Journal of Colloid and Interface Science.

[10]  H. Yao,et al.  Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage , 2021, Journal of proteome research.

[11]  L. Du,et al.  Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients , 2021, BMC Infectious Diseases.

[12]  N. Qureshi,et al.  Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK , 2020, Atherosclerosis.

[13]  C. Cannon,et al.  Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). , 2020, Journal of clinical lipidology.

[14]  S. Solomon,et al.  COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease , 2020, European journal of heart failure.

[15]  M. Banach,et al.  Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic , 2020, Pharmacological Research.

[16]  Wenjuan Zeng,et al.  Hypolipidemia is associated with the severity of COVID-19 , 2020, Journal of Clinical Lipidology.

[17]  David Moher,et al.  CARE guidelines for case reports: explanation and elaboration document. , 2017, Journal of clinical epidemiology.

[18]  A. Marais,et al.  Efficacy criteria and cholesterol targets for LDL apheresis. , 2010, Atherosclerosis.